Description
Join us to learn more about a CDK 4 & 6 inhibitor with overall survival data for women with HR+, HER2- metastatic breast cancer, including those likely to do worse.
Speaker(s):
- Blanca
Ledezma,
MSN, NP,
Nurse Practitioner,
UCLA Santa Monica Hematology/Oncology
